Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions

Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics (PK), pharmacodynamics, efficacy, and toxicity was simulated for scenario...

Full description

Saved in:
Bibliographic Details
Published inCPT: pharmacometrics and systems pharmacology Vol. 7; no. 11; pp. 771 - 779
Main Authors Clements, John David, Perez Ruixo, Juan Jose, Gibbs, John P., Doshi, Sameer, Perez Ruixo, Carlos, Melhem, Murad
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.11.2018
John Wiley and Sons Inc
Subjects
Online AccessGet full text
ISSN2163-8306
2163-8306
DOI10.1002/psp4.12354

Cover

Loading…
Abstract Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics (PK), pharmacodynamics, efficacy, and toxicity was simulated for scenarios characterized by varying degrees of different types of variability. Receiver operating characteristic (ROC) and clinical trial simulation (CTS) were used to optimize drug titration by maximizing efficacy/safety. The scenarios included were a low‐variability base scenario, and high residual (20%), interoccasion (20%), interindividual (40%), and residual plus interindividual variability scenarios, and finally a shallow toxicity slope scenario. The percentage of subjects having toxicity was reduced by 87.4% to 93.5%, and those having efficacy was increased by 52.7% to 243%. Interindividual PK variability may have less impact on optimal cutoff values than other sources of variability. ROC/CTS methods for optimizing dose titration offer an individualized approach that leverages exposure‐response relationships.
AbstractList Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics (PK), pharmacodynamics, efficacy, and toxicity was simulated for scenarios characterized by varying degrees of different types of variability. Receiver operating characteristic (ROC) and clinical trial simulation (CTS) were used to optimize drug titration by maximizing efficacy/safety. The scenarios included were a low-variability base scenario, and high residual (20%), interoccasion (20%), interindividual (40%), and residual plus interindividual variability scenarios, and finally a shallow toxicity slope scenario. The percentage of subjects having toxicity was reduced by 87.4% to 93.5%, and those having efficacy was increased by 52.7% to 243%. Interindividual PK variability may have less impact on optimal cutoff values than other sources of variability. ROC/CTS methods for optimizing dose titration offer an individualized approach that leverages exposure-response relationships.
Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics ( PK ), pharmacodynamics, efficacy, and toxicity was simulated for scenarios characterized by varying degrees of different types of variability. Receiver operating characteristic ( ROC ) and clinical trial simulation ( CTS ) were used to optimize drug titration by maximizing efficacy/safety. The scenarios included were a low‐variability base scenario, and high residual (20%), interoccasion (20%), interindividual (40%), and residual plus interindividual variability scenarios, and finally a shallow toxicity slope scenario. The percentage of subjects having toxicity was reduced by 87.4% to 93.5%, and those having efficacy was increased by 52.7% to 243%. Interindividual PK variability may have less impact on optimal cutoff values than other sources of variability. ROC / CTS methods for optimizing dose titration offer an individualized approach that leverages exposure‐response relationships.
Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics (PK), pharmacodynamics, efficacy, and toxicity was simulated for scenarios characterized by varying degrees of different types of variability. Receiver operating characteristic (ROC) and clinical trial simulation (CTS) were used to optimize drug titration by maximizing efficacy/safety. The scenarios included were a low-variability base scenario, and high residual (20%), interoccasion (20%), interindividual (40%), and residual plus interindividual variability scenarios, and finally a shallow toxicity slope scenario. The percentage of subjects having toxicity was reduced by 87.4% to 93.5%, and those having efficacy was increased by 52.7% to 243%. Interindividual PK variability may have less impact on optimal cutoff values than other sources of variability. ROC/CTS methods for optimizing dose titration offer an individualized approach that leverages exposure-response relationships.Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics (PK), pharmacodynamics, efficacy, and toxicity was simulated for scenarios characterized by varying degrees of different types of variability. Receiver operating characteristic (ROC) and clinical trial simulation (CTS) were used to optimize drug titration by maximizing efficacy/safety. The scenarios included were a low-variability base scenario, and high residual (20%), interoccasion (20%), interindividual (40%), and residual plus interindividual variability scenarios, and finally a shallow toxicity slope scenario. The percentage of subjects having toxicity was reduced by 87.4% to 93.5%, and those having efficacy was increased by 52.7% to 243%. Interindividual PK variability may have less impact on optimal cutoff values than other sources of variability. ROC/CTS methods for optimizing dose titration offer an individualized approach that leverages exposure-response relationships.
Author Gibbs, John P.
Perez Ruixo, Juan Jose
Perez Ruixo, Carlos
Melhem, Murad
Clements, John David
Doshi, Sameer
AuthorAffiliation 1 Clinical Pharmacology and Modeling & Simulation Amgen Inc. Thousand Oaks California USA
4 Clinical Pharmacology Vertex Pharmaceuticals Boston Massachusetts USA
2 Clinical Pharmacology and Pharmacometrics Janssen Research and Development Beerse Belgium
3 Clinical Pharmacology and Pharmacometrics AbbVie North Chicago Illinois USA
AuthorAffiliation_xml – name: 4 Clinical Pharmacology Vertex Pharmaceuticals Boston Massachusetts USA
– name: 2 Clinical Pharmacology and Pharmacometrics Janssen Research and Development Beerse Belgium
– name: 3 Clinical Pharmacology and Pharmacometrics AbbVie North Chicago Illinois USA
– name: 1 Clinical Pharmacology and Modeling & Simulation Amgen Inc. Thousand Oaks California USA
Author_xml – sequence: 1
  givenname: John David
  surname: Clements
  fullname: Clements, John David
  email: clementj@amgen.com
  organization: Amgen Inc
– sequence: 2
  givenname: Juan Jose
  surname: Perez Ruixo
  fullname: Perez Ruixo, Juan Jose
  organization: Janssen Research and Development
– sequence: 3
  givenname: John P.
  surname: Gibbs
  fullname: Gibbs, John P.
  organization: AbbVie
– sequence: 4
  givenname: Sameer
  surname: Doshi
  fullname: Doshi, Sameer
  organization: Amgen Inc
– sequence: 5
  givenname: Carlos
  surname: Perez Ruixo
  fullname: Perez Ruixo, Carlos
  organization: Janssen Research and Development
– sequence: 6
  givenname: Murad
  surname: Melhem
  fullname: Melhem, Murad
  organization: Vertex Pharmaceuticals
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30246497$$D View this record in MEDLINE/PubMed
BookMark eNp9kV1rHCEUhqWkNB_NTX9AEXpTApuqo87OTSFs-hEIJDTba3H0TGLq6FRnUvbf182kIQ2lXujB87wv52Mf7YQYAKE3lBxTQtiHIQ_8mLJK8Bdoj1FZLZYVkTtP4l10mPMtKafmhDbkFdqtCOOSN_Ue-vENDLg7SPhigKRHF67x6kYnbUZILo_O4JOg_Sa7jHWweOVdcEZ7vE6u3Feun3xRxYDHiM9CF1OPT2MGvHZjmhOnYFwuQX6NXnbaZzh8eA_Q98-f1quvi_OLL2erk_OF4XzJF01lBGXG1h0zsoWG6PIh67prtADRlT5oa-vW2hpkba0htgPWUCK0aCRdttUB-jj7DlPbgzUQSileDcn1Om1U1E79nQnuRl3HOyWZrKSkxeD9g0GKPyfIo-pdNuC9DhCnrBiltOZCCFbQd8_Q2zilMrFCMSnZUlK2pd4-reixlD97KMDRDJgUc07QPSKUqO2e1XbP6n7PBSbPYOPG-1mXbpz_t4TOkl_Ow-Y_5ury6pLPmt9fP7tG
CitedBy_id crossref_primary_10_1192_bjp_2023_27
crossref_primary_10_1002_psp4_12613
crossref_primary_10_1002_psp4_12464
Cites_doi 10.1111/j.1365-2125.2001.00971.x
10.3348/kjr.2004.5.1.11
10.1158/1078-0432.CCR-03-0785
10.1248/yakushi.129.749
10.1002/psp4.12106
10.1148/radiology.143.1.7063747
10.1097/FTD.0000000000000061
10.1016/j.jacc.2005.06.061
10.1002/0471722146
10.1007/s11095-006-9202-3
10.1038/clpt.2009.199
10.1177/193229681100500127
10.1177/0091270004271945
10.2165/00003088-200948050-00002
10.1097/00007691-200406000-00019
10.1016/j.bios.2014.03.047
10.1007/s00280-011-1714-9
10.2165/00003088-200847080-00001
10.1177/0091270010377201
10.1081/BIP-120037192
10.2165/00003088-200544020-00002
10.1023/A:1020953107162
10.1093/clinchem/39.4.561
10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
10.1097/FTD.0000000000000009
ContentType Journal Article
Copyright 2018 The Authors published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.
2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.
2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2018 The Authors published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.
– notice: 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.
– notice: 2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1002/psp4.12354
DatabaseName Wiley Online Library Open Access
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
Publicly Available Content Database

CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2163-8306
EndPage 779
ExternalDocumentID PMC6263661
30246497
10_1002_psp4_12354
PSP412354
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 0R~
1OC
24P
5VS
7X7
8FI
8FJ
AAHHS
AAZKR
ABDBF
ABUWG
ACCFJ
ACCMX
ACGFS
ACUHS
ACXQS
ADBBV
ADKYN
ADPDF
ADRAZ
ADZMN
ADZOD
AEEZP
AEQDE
AFKRA
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
DIK
EBS
EJD
FYUFA
GODZA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
ITC
KQ8
M48
M~E
O9-
OK1
OVD
PIMPY
PQQKQ
PROAC
RNTTT
RPM
TEORI
TUS
UKHRP
WIN
AAYXX
CITATION
PHGZM
PHGZT
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c4484-93c512cd7f2c6be90a3c5677f9a5e5f0001bd7bdd7e67ddc0dfe29105a59618b3
IEDL.DBID M48
ISSN 2163-8306
IngestDate Thu Aug 21 18:26:40 EDT 2025
Fri Sep 05 09:22:20 EDT 2025
Fri Jul 25 06:07:08 EDT 2025
Thu Apr 03 07:02:53 EDT 2025
Thu Apr 24 22:58:23 EDT 2025
Tue Jul 01 02:21:37 EDT 2025
Wed Jan 22 16:46:13 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License Attribution-NonCommercial
2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4484-93c512cd7f2c6be90a3c5677f9a5e5f0001bd7bdd7e67ddc0dfe29105a59618b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1002/psp4.12354
PMID 30246497
PQID 2266286122
PQPubID 4368367
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6263661
proquest_miscellaneous_2111745552
proquest_journals_2266286122
pubmed_primary_30246497
crossref_primary_10_1002_psp4_12354
crossref_citationtrail_10_1002_psp4_12354
wiley_primary_10_1002_psp4_12354_PSP412354
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2018
PublicationDateYYYYMMDD 2018-11-01
PublicationDate_xml – month: 11
  year: 2018
  text: November 2018
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle CPT: pharmacometrics and systems pharmacology
PublicationTitleAlternate CPT Pharmacometrics Syst Pharmacol
PublicationYear 2018
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
References 2009; 86
2011
2004; 26
2004; 5
1982; 143
2011; 5
2005; 44
2005; 45
2009; 48
2005; 46
2004; 10
2016; 5
2002; 29
1993; 39
2000
2008; 29
2004; 14
2013; 30
2008; 47
2014; 59
2014; 36
2014
2009; 129
2012; 69
2012; 66
1991; 148
2007; 24
1950; 3
2001; 52
2010; 50
1989
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_22_1
Perry P.J. (e_1_2_10_21_1) 1991; 148
Acuna C. (e_1_2_10_8_1) 2013; 30
e_1_2_10_1_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_12_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_10_1
e_1_2_10_11_1
e_1_2_10_32_1
Beal S. (e_1_2_10_30_1) 1989
Jelic I. (e_1_2_10_15_1) 2012; 66
Florkowski C.M. (e_1_2_10_20_1) 2008; 29
e_1_2_10_29_1
Bauer R. (e_1_2_10_31_1) 2011
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – year: 2011
– volume: 59
  start-page: 233
  year: 2014
  end-page: 238
  article-title: Detection of the antiepileptic drug phenytoin using a single free‐standing piezoresistive microcantilever for therapeutic drug monitoring
  publication-title: Biosens. Bioelectron.
– volume: 36
  start-page: 606
  year: 2014
  end-page: 611
  article-title: Trough concentration over 12.1 mg/l is a major risk factor of vancomycin‐related nephrotoxicity in patients with therapeutic drug monitoring
  publication-title: Ther. Drug Monit.
– volume: 44
  start-page: 147
  year: 2005
  end-page: 173
  article-title: Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review
  publication-title: Clin. Pharmacokinet.
– volume: 66
  start-page: 157
  year: 2012
  end-page: 164
  article-title: [Opatija study: observation of hemodialysis patients and titration of cera dose just switched from another erythropoiesis stimulating agent]
  publication-title: Acta Med. Croatica
– volume: 39
  start-page: 561
  year: 1993
  end-page: 577
  article-title: Receiver‐operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine
  publication-title: Clin. Chem.
– volume: 47
  start-page: 487
  year: 2008
  end-page: 513
  article-title: Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology
  publication-title: Clin. Pharmacokinet.
– volume: 5
  start-page: 484
  year: 2016
  end-page: 494
  article-title: Population pharmacokinetics and pharmacodynamics of the calcimimetic etelcalcetide in chronic kidney disease and secondary hyperparathyroidism receiving hemodialysis
  publication-title: CPT Pharmacometrics Syst. Pharmacol.
– year: 1989
– volume: 29
  start-page: 339
  year: 2002
  end-page: 363
  article-title: Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris
  publication-title: J. Pharmacokinet. Pharmacodyn.
– volume: 30
  start-page: 585
  year: 2013
  end-page: 590
  article-title: [Pharmacokinetics of vancomycin in children hospitalized in a critical care unit]
  publication-title: Rev. Chilena Infectol.
– volume: 5
  start-page: 192
  year: 2011
  end-page: 197
  article-title: Diabetes and biomarkers
  publication-title: J. Diabetes Sci. Technol.
– year: 2000
– volume: 29
  start-page: S83
  issue: suppl. 1
  year: 2008
  end-page: S87
  article-title: Sensitivity, specificity, receiver‐operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests
  publication-title: Clin. Biochem. Rev.
– volume: 52
  start-page: 55s
  issue: suppl. 1
  year: 2001
  end-page: 59s
  article-title: Target concentration intervention: beyond y2k
  publication-title: Br. J. Clin. Pharmacol.
– volume: 26
  start-page: 331
  year: 2004
  end-page: 335
  article-title: A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation
  publication-title: Ther. Drug Monit.
– volume: 10
  start-page: 3885
  year: 2004
  end-page: 3896
  article-title: Rationale for biomarkers and surrogate end points in mechanism‐driven oncology drug development
  publication-title: Clin. Cancer Res.
– volume: 3
  start-page: 32
  year: 1950
  end-page: 35
  article-title: Index for rating diagnostic tests
  publication-title: Cancer
– volume: 45
  start-page: 246
  year: 2005
  end-page: 256
  article-title: Population pharmacokinetic analysis and simulation of the time‐concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis
  publication-title: J. Clin. Pharmacol.
– year: 2014
– volume: 5
  start-page: 11
  year: 2004
  end-page: 18
  article-title: Receiver operating characteristic (ROC) curve: practical review for radiologists
  publication-title: Korean J. Radiol.
– volume: 86
  start-page: 667
  year: 2009
  end-page: 671
  article-title: Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon‐like peptide‐2 analog in neonates and infants with short‐bowel syndrome
  publication-title: Clin. Pharmacol. Ther.
– volume: 129
  start-page: 749
  year: 2009
  end-page: 757
  article-title: Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log‐binominal regression for febrile neutropenia
  publication-title: Yakugaku Zasshi
– volume: 48
  start-page: 301
  year: 2009
  end-page: 311
  article-title: Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride
  publication-title: Clin. Pharmacokinet.
– volume: 69
  start-page: 447
  year: 2012
  end-page: 455
  article-title: Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation
  publication-title: Cancer Chemother. Pharmacol.
– volume: 24
  start-page: 791
  year: 2007
  end-page: 802
  article-title: Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation
  publication-title: Pharm. Res.
– volume: 148
  start-page: 231
  year: 1991
  end-page: 235
  article-title: Clozapine and norclozapine plasma concentrations and clinical response of treatment‐refractory schizophrenic patients
  publication-title: Am. J. Psychiatry
– volume: 50
  start-page: 75s
  year: 2010
  end-page: 90s
  article-title: Exposure‐response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis
  publication-title: J. Clin. Pharmacol.
– volume: 36
  start-page: 335
  year: 2014
  end-page: 344
  article-title: Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain
  publication-title: Ther. Drug Monit.
– volume: 143
  start-page: 29
  year: 1982
  end-page: 36
  article-title: The meaning and use of the area under a receiver operating characteristic (ROC) curve
  publication-title: Radiology
– volume: 14
  start-page: 451
  year: 2004
  end-page: 467
  article-title: Simulating titration to goal clinical trials with statins
  publication-title: J. Biopharm. Stat.
– volume: 46
  start-page: 1322
  year: 2005
  end-page: 1330
  article-title: Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia
  publication-title: J. Am. Coll. Cardiol.
– ident: e_1_2_10_5_1
  doi: 10.1111/j.1365-2125.2001.00971.x
– volume: 66
  start-page: 157
  year: 2012
  ident: e_1_2_10_15_1
  article-title: [Opatija study: observation of hemodialysis patients and titration of cera dose just switched from another erythropoiesis stimulating agent]
  publication-title: Acta Med. Croatica
– volume: 29
  start-page: S83
  issue: 1
  year: 2008
  ident: e_1_2_10_20_1
  article-title: Sensitivity, specificity, receiver‐operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests
  publication-title: Clin. Biochem. Rev.
– ident: e_1_2_10_19_1
  doi: 10.3348/kjr.2004.5.1.11
– ident: e_1_2_10_13_1
  doi: 10.1158/1078-0432.CCR-03-0785
– ident: e_1_2_10_4_1
  doi: 10.1248/yakushi.129.749
– ident: e_1_2_10_17_1
  doi: 10.1002/psp4.12106
– ident: e_1_2_10_27_1
  doi: 10.1148/radiology.143.1.7063747
– ident: e_1_2_10_10_1
  doi: 10.1097/FTD.0000000000000061
– ident: e_1_2_10_1_1
  doi: 10.1016/j.jacc.2005.06.061
– ident: e_1_2_10_32_1
– ident: e_1_2_10_22_1
  doi: 10.1002/0471722146
– volume-title: NONMEM Users Guide: Introduction to nonmem 7.2
  year: 2011
  ident: e_1_2_10_31_1
– volume: 148
  start-page: 231
  year: 1991
  ident: e_1_2_10_21_1
  article-title: Clozapine and norclozapine plasma concentrations and clinical response of treatment‐refractory schizophrenic patients
  publication-title: Am. J. Psychiatry
– ident: e_1_2_10_3_1
  doi: 10.1007/s11095-006-9202-3
– ident: e_1_2_10_24_1
  doi: 10.1038/clpt.2009.199
– ident: e_1_2_10_14_1
  doi: 10.1177/193229681100500127
– ident: e_1_2_10_2_1
  doi: 10.1177/0091270004271945
– ident: e_1_2_10_16_1
  doi: 10.2165/00003088-200948050-00002
– ident: e_1_2_10_12_1
  doi: 10.1097/00007691-200406000-00019
– ident: e_1_2_10_11_1
  doi: 10.1016/j.bios.2014.03.047
– ident: e_1_2_10_18_1
  doi: 10.1007/s00280-011-1714-9
– ident: e_1_2_10_7_1
  doi: 10.2165/00003088-200847080-00001
– volume: 30
  start-page: 585
  year: 2013
  ident: e_1_2_10_8_1
  article-title: [Pharmacokinetics of vancomycin in children hospitalized in a critical care unit]
  publication-title: Rev. Chilena Infectol.
– ident: e_1_2_10_26_1
  doi: 10.1177/0091270010377201
– ident: e_1_2_10_25_1
  doi: 10.1081/BIP-120037192
– ident: e_1_2_10_6_1
  doi: 10.2165/00003088-200544020-00002
– volume-title: NONMEM User's Guides
  year: 1989
  ident: e_1_2_10_30_1
– ident: e_1_2_10_23_1
  doi: 10.1023/A:1020953107162
– ident: e_1_2_10_28_1
  doi: 10.1093/clinchem/39.4.561
– ident: e_1_2_10_29_1
  doi: 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
– ident: e_1_2_10_9_1
  doi: 10.1097/FTD.0000000000000009
SSID ssj0000740190
Score 2.1278763
Snippet Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 771
SubjectTerms Algorithms
Clinical trials
Drug dosages
Efficiency
Studies
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-0vvgirZ-xVUaUgtLYXLKbTZ5EWksR1INe4d7CfgUPa5I214f-953Z7OU8Kn0L2Qn5mNmZX2Z3fsPYB5MZWbrExnVdq5iLLImVnqg419KaiU1V7nO6P37mp-f8-1zMQ8KtD9sqVz7RO2rbGsqRHyJMoCrKSZp-6S5j6hpFq6uhhcZD9shTl6E9y7kccywJtZsrk5GVND3s-o5_pvJQvhmH7oDLu3sk_8WuPvicbLMnATXC10HNO-yBa56y_elAO31zALN1FVV_APswXRNS3zxjfxAbOtp_Ab864lDGaAVHG0TNsOImAdVYCFyhFzAj64Szxd_Q4wuWLQz1S3Dc9g5mi0C6C8ehVU__nJ2ffJsdncahyUJs8M-Mx2VmMOYbK-vU5NqVicITuZR1qYQTNWFAbaW2VrpcWmsSW7sUMYZQgprF6OwF22raxr1ikBUqtXRhgYG_1rnWBXrPglt0uEWSmYh9XH3yygQGcmqEcVEN3MlpReqpvHoi9n6U7Qbejf9K7a00V4W511drS4nYu3EYZw0thajGtdcogy5eciEEyrwcFD3eJsOnz3kpIyY3TGAUIEbuzZFm8dszcxO1DwKeiH3yxnLPk1fTsyn3R6_vf4dd9hgxWjGUP-6xreXVtXuDOGip33pjvwW2ggtq
  priority: 102
  providerName: ProQuest
– databaseName: Wiley Online Library Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fS9xAEB6sffGl1NbatCpbWoSK0dxmN5uAL0UrUqgGPMG3sL9Cj9rc0ZwP_ved2eRyHpZC30J2liyZnZkvk51vAD7Z1KrCJy6u61rHQqZJrM1Ix5lRzo4c11nI6X6_zC5uxLdbebsGJ4tamI4fYki4kWUEf00Grk17vCQNnbUzcUSVnuIZPKfaWmrcwEU5ZFgSajYXkiwcQUecIzge-En58XL6akR6AjOfnpZ8jGJDGDp_CS96_Mi-dArfhDXfvIL9siOgfjhk42U9VXvI9lm5pKZ-eA0_ESV6OonBrmbEpoxxi52uUDazBUsJ041jPWvoHRvTPmXXk199ty82n7KukomdTVvPxpOefped9U172i24Of86Pr2I-3YLscVvNBEXqcXob52quc2MLxKNNzKl6kJLL2tCg8Yp45zymXLOJq72HNGG1JLaxpj0Daw308a_BZbmmjuamCMEqE1mTI5-NBcOXW-epDaCz4tXXtmei5xaYtxVHYsyr0g9VVBPBB8H2VnHwPFXqZ2F5qreCtsKoSVV3o44j-DDMIz2Qz9FdOOn9yiDzl4JKSXKbHeKHh6T4uozUagI1MoWGASIm3t1pJn8CBzdRPKD0CeCg7BZ_rHyqrwuRbh69z_C72EDsVvelUXuwPr8973fRXw0N3vBDP4AiFEOJg
  priority: 102
  providerName: Wiley-Blackwell
Title Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpsp4.12354
https://www.ncbi.nlm.nih.gov/pubmed/30246497
https://www.proquest.com/docview/2266286122
https://www.proquest.com/docview/2111745552
https://pubmed.ncbi.nlm.nih.gov/PMC6263661
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ra9swED_6gNEvY93Taxc0NgobdevYsmV_KGPrY2XQzqwJ5JvRyywsc9I6heW_30mW3YR2-yKMdcJCd9L9JOt-B_BeRpJlOlB-WZbcp3EU-Fz0uZ8IpmRfhTyxZ7oXl8n5kH4bxaM1aPN3ugGsH9zamXxSw5vJwZ_rxSec8EeOQPRwVs_ogYn5pOuwiR4pMZuwCwfz7Yps0s5lQcdOutxkCx5F6KcSamifll3TPbx5_9rkMpy1_ujsCTx2QJJ8bjS_DWu6egp7ecNEvdgng7vAqnqf7JH8jqN68Qx-IVzU5koG-T4ztMrowMjxCnczaelKCK8UcfShEzIwBkuuxr9d2i8yn5ImpImcTGtNBmPHw0tOXPae-jkMz04Hx-e-y7vgS9ysUT-LJMIAqVgZykToLOD4ImGszHis49LAQqGYUIrphCklA1XqEGFHzGOTP0ZEL2Cjmlb6FZAo5aEyDVMc41IkQqS4oKZU4RqcBpH04EM75IV0pOQmN8akaOiUw8JoqrCa8uBdJztrqDgelNptNVe01lQgxjQhuP0w9OBtV40Tyfwd4ZWe3qIMrvqMxnGMMi8bRXefaS3EA7ZiAp2AIeleranGPy1Zt2H7QQzkwUdrLP_peZFf5dQ-vf5nB3ZgCxFb2gRD7sLG_OZWv0FUNBc9WA9pjiUbsR5sfjm9zH_07AkDll9H_Z6dEn8BrvESkw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6V9AAXxBtDgUVAJVBNnfXaax8QgqZVStsQUVfqzezLIqLYBqdC-VP8Rmb9ClFRb71Z9thee2Z2vn3MNwAvla94bDztZlkmXBb4nivkULih5FoNNRVhPad7NAnHJ-zTaXC6Bn-6XBi7rbLrE-uOWhfKzpFvI0ywWZRDSt-XP11bNcqurnYlNBqzODCL3zhkq97tj1C_ryjd2012xm5bVcBVOBRhbuwrDHJK84yqUJrYE3gi5DyLRWCCzIIeqbnUmpuQa608nRmKQTUQga2OIn187jVYZzajdQDrH3cn0y_9rI5nC9zFXs-DSrfLqmRvbUIqW418F-DsxV2Z_6LlOtzt3YKbLU4lHxrDug1rJr8Dm9OG6HqxRZJl3la1RTbJdEmBvbgL3xGNGrvjg3wuLWszxkeys0INTTo2FCJyTVp20jOSWH8gx7MfbVUxMi9IkzFFRkVlSDJraX7JqC0OVN2DkytRwH0Y5EVuHgLxI0G1vTFCqJHJUMoI--uIaeziI89XDrzufnmqWs5zW3rjLG3Ymmlq1ZPW6nHgRS9bNkwf_5Xa6DSXtt5epUvbdOB5fxn91C6-iNwU5yiDQYWzIAhQ5kGj6P41PrY-ZDF3gK-YQC9gOcBXr-SzbzUXuCUTQojlwJvaWC5peTo9nrL66NHl3_AMro-To8P0cH9y8BhuIEKMmuTLDRjMf52bJ4jC5vJpa_oEvl61t_0F6_BKKw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIiEuFW9SChgBlUBNN-s4cXJACHVZtRRKpG6lvQW_oq4oSdpshfav8esY57WsinrrLYonL8-M57Pj-QbgjfIVj42n3SzLhMsC33OFHAo3lFyroaYirNd0vx2F-yfsyzSYrsGfLhfGbqvsxsR6oNaFsmvkA4QJNotySOkga7dFJKPxx_LctRWk7J_WrpxGYyKHZvEbp2_Vh4MR6votpePPk719t60w4CqcljA39hUGPKV5RlUoTewJPBFynsUiMEFmAZDUXGrNTci1Vp7ODMUAG4jAVkqRPt73FtzmPqIq9CU-5f36jmdL3cVez4hKB2VVsl2bmspWY-AVYHt1f-a_uLkOfON7sNEiVvKpMbH7sGbyB7CdNJTXix0yWWZwVTtkmyRLMuzFQ_iJuNTYvR_ke2n5mzFSkr0VkmjS8aIQkWvS8pSekYn1DHI8-9XWFyPzgjS5U2RUVIZMZi3hLxm1ZYKqR3ByI93_GNbzIjdPgfiRoNpeGCHoyGQoZYQjd8Q0DvaR5ysH3nVdnqqW_dwW4ThLG95mmlr1pLV6HHjdy5YN58d_pbY6zaWt31fp0kodeNU3o8fa3zAiN8UlymB44SwIApR50ii6f4yPbx-ymDvAV0ygF7Bs4Kst-ey0ZgW3tEIIthx4XxvLNW-eJscJq482r_-Gl3AHfSz9enB0-AzuIlSMmizMLVifX1ya5wjH5vJFbfcEfty0o_0FS6FM8g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Receiver+Operating+Characteristic+Analysis+and+Clinical+Trial+Simulation+to+Inform+Dose+Titration+Decisions&rft.jtitle=CPT%3A+pharmacometrics+and+systems+pharmacology&rft.au=Clements%2C+John+David&rft.au=Perez+Ruixo%2C+Juan+Jose&rft.au=Gibbs%2C+John+P&rft.au=Doshi%2C+Sameer&rft.date=2018-11-01&rft.eissn=2163-8306&rft.volume=7&rft.issue=11&rft.spage=771&rft_id=info:doi/10.1002%2Fpsp4.12354&rft_id=info%3Apmid%2F30246497&rft.externalDocID=30246497
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2163-8306&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2163-8306&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2163-8306&client=summon